A detailed history of Parallel Advisors, LLC transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 99 shares of TGTX stock, worth $2,924. This represents 0.0% of its overall portfolio holdings.

Number of Shares
99
Previous 44 125.0%
Holding current value
$2,924
Previous $0 Infinity%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$17.21 - $25.28 $946 - $1,390
55 Added 125.0%
99 $2,000
Q2 2024

Aug 08, 2024

BUY
$13.32 - $19.19 $586 - $844
44 New
44 $0
Q1 2023

May 20, 2024

BUY
$10.23 - $19.34 $4,450 - $8,412
435 New
435 $6,000
Q2 2022

Aug 01, 2022

BUY
$3.74 - $10.66 $1,626 - $4,637
435 New
435 $2,000
Q1 2022

Apr 28, 2022

SELL
$7.81 - $20.45 $4,123 - $10,797
-528 Closed
0 $0
Q4 2021

Jan 20, 2022

BUY
$15.2 - $35.51 $7,265 - $16,973
478 Added 956.0%
528 $10,000
Q2 2021

Aug 06, 2021

SELL
$32.5 - $48.96 $455 - $685
-14 Reduced 21.88%
50 $2,000
Q4 2020

Feb 02, 2021

BUY
$25.27 - $54.9 $480 - $1,043
19 Added 42.22%
64 $3,000
Q2 2020

Jul 16, 2020

BUY
$8.9 - $21.84 $400 - $982
45 New
45 $0

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.29B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.